Teva Pharmaceuticals, recall and blood pressure
Digest more
The Israeli pharmaceutical company, managed by CEO Richard Francis, will publish its third quarter financial results on ...
Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding ...
Zacks Investment Research on MSN
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA) to post quarterly earnings of $0.68 per share in its upcoming report, which indicates a year-over-year decline of 1.5%. Revenues ...
The main Irish arm of Israeli-headquartered pharmaceutical firm Teva last year paid out dividends of $709.5 million (€617.9 ...
TipRanks on MSN
Teva launches ‘The Other TD’ disease education campaign
Pharmaceuticals announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football ...
Investor's Business Daily on MSN
IBD Rating Upgrades: Teva Pharmaceutical ADR Flashes Improved Price Strength
A Relative Strength Rating upgrade for Teva Pharmaceutical ADR shows improving technical performance. Will it continue?
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback